2. Academic Validation
  3. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii

  • Int J Antimicrob Agents. 2018 Jan;51(1):62-64. doi: 10.1016/j.ijantimicag.2017.06.022.
Harald Seifert 1,  Danuta Stefanik 2,  Joyce A Sutcliffe 3,  Paul G Higgins 4
Affiliations

Affiliations

  • 1 Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany. Electronic address: [email protected].
  • 2 Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany.
  • 3 Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA.
  • 4 Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Germany.
PMID: 28705668 DOI: 10.1016/j.ijantimicag.2017.06.022
Abstract

The activity of eravacycline was compared with that of anti-Acinetobacter reference antimicrobials against carbapenem non-susceptible Acinetobacter baumannii isolates associated with an acquired OXA or up-regulation of the intrinsic OXA-51-like Enzyme. Antimicrobial susceptibility testing was performed by broth microdilution of 286 non-duplicate, carbapenem non-susceptible A. baumannii isolates to eravacycline, amikacin colistin, doxycycline, imipenem, levofloxacin, meropenem, minocycline, sulbactam, tigecycline and tobramycin. Eravacycline showed greater activity than the comparators of the Tetracycline class, levofloxacin, amikacin, tobramycin and colistin. The eravacycline MIC50/90 values were 0.5/1 mg/L and those for tigecycline, minocycline and doxycycline were 1/2, 4/8 and 32/ ≥ 64 mg/L, respectively. In conclusion, eravacycline was the most potent Antibiotic of those tested against A. baumannii, including isolates that were resistant to sulbactam, imipenem/meropenem, levofloxacin and amikacin/tobramycin. Eravacycline has the potential to become a useful addition to the limited armamentarium of drugs that can be used to treat this problem pathogen.

Keywords

Colistin; International clone; Multidrug-resistance; Oxacillinase; Tetracycline; Tigecycline.

Figures
Products